| Quarter | Score |
|---|---|
| 2022-Q1 | 49.4 |
| 2022-Q3 | 65.6 |
| 2022-Q4 | 49.1 |
| 2023-Q1 | 49.0 |
| 2023-Q2 | 63.5 |
| 2023-Q3 | 51.7 |
| 2023-Q4 | 65.6 |
| 2024-Q1 | 70.1 |
| 2024-Q2 | 52.2 |
| 2024-Q3 | 80.1 |
| 2024-Q4 | 77.8 |
| 2025-Q1 | 78.1 |
| 2025-Q2 | 77.6 |
| 2025-Q3 | 77.4 |
| 2025-Q4 | 76.8 |
| 2026-Q1 | 77.7 |
| 2026-Q2 | 79.0 |
Funds reducing exposure or consensus momentum fading
Trading +23.8% above funds' purchase price — elevated pullback risk
2 of 18 tracked funds hold DVA. Avg conviction: 1.1%. Net trimming. First tracked at $151.25 (current +23.8% vs tracked).
Berkshire Hathaway has 2.1% in this stock
Prices are approximate, based on 13F reported values (position value / shares), not actual cost basis. Data covers 17 tracked value-oriented funds. Holdings are reported quarterly with a ~45-day lag. Stock splits may affect share count comparisons. Returns are not annualized.
| Fund | % of Portfolio | Action |
|---|---|---|
| Berkshire Hathaway | 2.1% | Reduce |
| Citadel Advisors | 0.0% | Reduce |